Key result
Tianeptine or sertraline treatment for 24 weeks significantly reduced depressive symptoms and improved quality of life in patients with ischemic heart disease compared to no antidepressant therapy.
Why the study?
Do antidepressants (tianeptine or sertraline) improve quality of life and reduce depression severity in patients with ischemic heart disease and comorbid depression?
RCT (n=90)
Open-label
Randomized
No
Do antidepressants (tianeptine or sertraline) improve quality of life and reduce depression severity in patients with ischemic heart disease and comorbid depression?
Absolute Event Rate: 8.8% vs 14.16%
p-value: p=<0.001
Antidepressant therapy with tianeptine or sertraline significantly improves quality of life and reduces depressive symptoms in patients with ischemic heart disease and comorbid depression.
Supports antidepressant use for comorbid depression in IHD; confirms symptom and QoL benefits in RCT.
Patients with ischemic heart disease (IHD) with depressive RAS disabilities are a special group of dispensary observation with a higher risk of cardiovascular complications than patients without depression. Timely detection of depressive disorders in IHD patients, the study of psychosocial factors, along with the known factors of cardiovascular risk, are essential components of modern diagnostic, medical and rehabilitation programs for patients with comorbid pathology in the polyclinic.
No takes yet. Share an insight, caveat, or question.
Yevsyukov et al. (2014) conducted an RCT in Ischemic heart disease with depressive disorders (n=90). Tianeptine or Sertraline vs. No antidepressant was evaluated on Hamilton Depression Rating Scale (HDRS) score at 24 weeks (p=<0.001). Tianeptine or sertraline treatment for 24 weeks significantly reduced depressive symptoms and improved quality of life in patients with ischemic heart disease compared to no antidepressant therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: